Abstract:Efficient T cell engineering is central to the success of CAR T cell therapy but involves multiple time-consuming manipulations, including T cell isolation, activation, and transduction. These steps add complexity and delay CAR T cell manufacturing, which takes a mean time of 4 weeks. To streamline T cell engineering, we strategically combine two critical engineering solutions - T cell-specific lentiviral vectors and macroporous scaffolds - that enable T cell activation and transduction in a simple, single step. The T cell-specific lentiviral vectors (referred to as STAT virus) target T cells through the display of an anti-CD3 antibody and the CD80 extracellular domain on their surface and provide robust T cell activation. Biocompatible macroporous scaffolds (referred to as Drydux) mediate robust transduction by providing effective interaction between naïve T cells and viral vectors. We show that when unstimulated peripheral blood mononuclear cells (PBMCs) are seeded together with STAT lentivirus on Drydux scaffolds, T cells are activated, selectively transduced, and reprogrammed in a single step. Further, we show that the Drydux platform seeded with PBMCs and STAT lentivirus generates tumor-specific functional CAR T cells. This potent combination of engineered lentivirus and biomaterial scaffold holds promise for an effective, simple, and safe avenue for in vitro and in vivo T cell engineering. Statement of Significance Manufacturing T cell therapies involves lengthy and labor-intensive steps, including T cell selection, activation, and transduction. These steps add complexity to current CAR T cell manufacturing protocols and limit widespread patient access to this revolutionary therapy. In this work, we demonstrate the combination of engineered virus and biomaterial platform that, together, enables selective T cell activation and transduction in a single step, eliminating multistep T cell engineering protocols and significantly simplifying the manufacturing process.

In vitro encapsulation and expansion of T and CAR-T cells using 3D synthetic thermo-responsive matrices

Fabrication and Evaluation of Electrohydrodynamic Jet 3d Printed Polycaprolactone/Chitosan Cell Carriers Using Human Embryonic Stem Cell-Derived Fibroblasts

In Vitro Assessment of Thermo‐Responsive Scaffold as a 3D Synthetic Matrix for CAR‐T Potency Testing Against Glioblastoma Spheroids

Thermosensitive polymeric matrices for three-dimensional cell culture strategies

3D Printed porous polyamide macrocapsule combined with alginate microcapsules for safer cell-based therapies

Heat-Inducible CAR-T Overcomes Adverse Mechanical Tumor Microenvironment in a 3D Bioprinted Glioblastoma Model

Macroencapsulation Devices for Cell Therapy

Engineering The Fate And Function Of Human T-Cells Via 3d Bioprinting

Synthetic Thermo-Responsive Terpolymers as Tunable Scaffolds for Cell Culture Applications

Materials approaches for next-generation encapsulated cell therapies

A Biomaterial Platform for T Cell-Specific Gene Delivery

Toroidal-spiral particles as a CAR-T cell delivery device for solid tumor immunotherapy

Injectable Supramolecular Hydrogels for in Situ Programming of Car‐T Cells Towards Solid Tumor Immunotherapy

CAR T cell infiltration and cytotoxic killing within the core of 3D breast cancer spheroids under the control of antigen sensing in microwell arrays

CAR T cell infiltration and cytotoxic killing within the core of 3D breast cancer spheroids under control of antigen sensing in microwell arrays

Bioinspired All-in-One Three-Dimensional Dynamic CellMatrix Improves the Manufacture of Therapeutically Qualified Cells for Cell Therapy

Engineering a clinically-useful matrix for cell therapy

Lymph node-biomimetic scaffold boosts CAR-T therapy against solid tumor

Injectable Supramolecular Hydrogels for in Situ Programming of Car-T Cells Toward Solid Tumor Immunotherapy

Engineered cell-laden thermosensitive poly(N-isopropylacrylamide)-immobilized gelatin microspheres as 3D cell carriers for regenerative medicine

Subcutaneous biodegradable scaffolds for restimulating the antitumour activity of pre-administered CAR-T cells